Imaging agent developer ImaginAb has entered into a development and manufacturing agreement for its PET imaging agent with Canada's Centre for Probe Development and Commercialization (CPDC).
Under the pact, the CPDC will manufacture and distribute ImaginAb's zirconium-89 (Zr-89) IAB22M2C for the company's phase II clinical trial sites, investigator-initiated trial sites, and studies conducted in collaboration with pharmaceutical companies in key global regions.
Zr-89 IAB22M2C is a clinical-stage PET imaging agent designed to assess changes in CD8+ T-cell tumor infiltrates due to immuno-oncological treatments. The goal is to guide the development of immuno-modulatory agents and provide an early assessment of whether a patient is responding to treatment.
